Introduction
encodes the entire HCV genome under the transcriptional control of the T7 polymerase promoter and a replicationdeficient adenovirus that encodes the T7 polymerase can act as a model for negative-strand HCV RNA synthesis and virus particle assembly (Myung et al., 2001) .
A selectable subgenomic HCV replicon system has been described that efficiently models the replication of both the plus and minus strands of HCV RNA, processing of the HCV polyprotein, and internal ribosomal entry site (IRES)-dependent translation of the selectable marker (Lohmann et al., 1999) . However, transfection of the human hepatoblastoma cell line, HUH-7 with these replicons resulted in colony formation with efficiency in the range of 0.0001-0.0005%. Continued passage of the transfected cells in selection media resulted in the accumulation of adaptive mutations in the HCV genome that led to an increase in the efficiency of colony formation of approximately 1000-to 20000-fold (Blight et al., 2000 .
In the above system, the replication of the replicon RNA is catalyzed by the HCV RdRp that is encoded by the replicon RNA itself. Here we describe a cell-based system in which the HCV RdRp utilizes an 'HCV-like' chimeric RNA as a template for RNA synthesis. This template consists of the firefly luciferase gene in the antisense orientation that is flanked by the 5′ and 3′ UTRs of the HCVnegative strand. This RNA is recognized by the HCV RNA-dependent RNA polymerase (RdRp) as a template and is transcribed into the orientation of the positive strand. This positive-strand-like RNA is translated in an IRES-dependent fashion producing luciferase that can be easily detected and quantified.
Materials and methods
Cell lines and culture conditions 293 (human embryonic kidney) cells were obtained from the American Type Culture Collection and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal bovine sera (FBS), penicillin (50 units per ml), and streptomycin (50 µg per ml) at 37°C and 5% CO 2 . Other cell lines were maintained in the above medium with the addition of the following selection agents: 293FL9 cells, G418 (500 µg per ml); 293B4α cells, zeocin (500 µg per ml) and G418 (500 µg per ml); 293SVLuc cells, zeocin (500 µg per ml). HUH-7 (FCCC) cells were a kind gift from Dr William Mason (Philadelphia, Pa., USA). HUH-7 (Apath) cells were licensed from Apath Corp. Hep G2 and HeLa cells were purchased from the ATCC. HUH-7 (FCCC), HUH-7 (Apath), Hep G2 and HeLa cells were maintained in DMEM supplemented with 10% FBS, minimal essential amino acids, penicillin and streptomycin.
Cells (1×10 6 cells in 500 µl DMEM per transfection) were transfected with 2 µg of plasmid DNA by electroporation (BioRad Corp., Hercules, Calif., USA, Gene Pulser; 1 pulse, 0.25 kV, and 960 µF). Cells were plated either in 35 mm plates or 100 mm plates in DMEM+FBS. Fortyeight hours post-transfection, the cells that were placed in 35 mm plates were assayed for luciferase activity as described below; cells plated in 100 mm plates were selected for the stable integration of the plasmids by placing them in DMEM, FBS and the appropriate selection agents.
Plasmids
The HCV 1b genome was encoded by plasmid pCX-HCV 1b. The transcription of plus-strand viral RNA is under the control of the cytomegalovirus immediate-early enhancer and chicken β-actin promoter. Furthermore, the 3′ terminus of the RNA transcribed from this plasmid is polyadenylated by the hepatitis B virus poly-adenylation signal.
The reporter plasmid, pMJ050 was created by placing, in order from 5′ to 3′, the HCV 1b 3′ UTR sequence (in the antisense orientation), the luciferase coding sequence (in the antisense orientation), the HCV 5′UTR including the first 39 bases of the core gene (in the antisense orientation), and the hepatitis δ ribozyme (in the sense orientation) into plasmid pZeoSV, under the control of the SV40 promoter. The luciferase gene from pGL3 (Promega, Madison, Wisc., USA) was placed under control of the SV40 promoter in pZeoSV (Invitrogen, Carlsbad, Calif., USA) to create a control plasmid, pSVLuc. The sequences of pMJ050 and pSVLuc were confirmed by automated DNA sequencing on an ABI Biosystems Prism DNA sequencer utilizing Rhodamine-labelled dideoxynucleotides and AmpliTaq polymerase FS.
The coding sequences of the HCV nonstructural proteins NS2, NS3 and NS5B were amplified by PCR from pCX-HCV1b and cloned individually into pMCS5 (MoBiTec, Marco Island. Fla., USA) to created pRK2CA, pRK470, and pRK401, respectively. The sequences for the HCV NS2 protease, NS3 serine protease, NS3 helicase and NS5B RdRp were mutated using the QuikChange Mutagenesis Kit and the mutagenic primers N2CAS, NS2CAA, 3PRMS, 3PRMA, 3HLMS, 3HLMA, 5BGAA, and 5BGAAS, respectively (Table 1) as directed by the manufacturer (Stratagene, La Jolla., Calif., USA). The mutated sequences were then cloned back into the HCV genome in plasmid, pCX-HCV1b to create plasmids, pRK426 (NS2 -), pRK475 (NS3Pr -), pRK480 (NS3Hl -), and pRK402 (NS5B -). The mutated sequences in pRK426 (NS2 -), pRK475 (NS3Pr -), pRK480 (NS3Hl -), and pRK402 (NS5B -) were reverted back to wild type using the mutagenic primers N2CASR, NS2CAAR, 3PRMRS, 3PRMRA, 3HLMRS, 3HLMRA, 5BGDDR, and 5BGDDA, respectively. The wild type sequences were then cloned back into pRK426 (NS2 -), pRK475 (NS3Pr -), pRK480 (NS3Hl -), and pRK402 (NS5B -) to create pRK426 (NS2 -) (wt), pRK475 (NS3Pr -) (wt), pRK480 (NS3Hl -) (wt), and pRK402 (NS5B -) (wt), respectively. In addition, the sequences for HCV NS3 and NS5b were cloned into pIRESneo2 (Clontech, Palo Alto, Calif., USA) to create pRKNS3 and pRKRdRp, respectively. Sequences for all plasmids were confirmed by automatic sequencing.
Western Blot analysis
Cells (1×10 6 cells per well) were plated in 6-well tissue culture plates. Twenty-four hours later, the cells were lysed in 50 µl of lysis buffer (50mM Tris, pH 8.0; 1mM EDTA; 1% NP-40). The lysate was clarified by microcentrifugation. Fifteen microlitres of the clarified lysate was mixed with 5 µl of 4X loading buffer (500mM Tris-HCl, pH 6.8; 4% SDS; 20% glycerol; 40mM DTT; 0.02% bromophenol blue) and boiled briefly before loading onto a 4-12% gradient polyacrylamide gel. Proteins were separated by size and transferred to a nitrocellulose filter.
HCV NS3 and NS5B proteins detected by Western blot analysis using monoclonal antibodies (mAbs) that were raised against Escherichia coli-derived recombinant HCV NS3 and NS5B proteins that were then shown to react specifically with these two proteins, respectively (data not shown). HCV core protein was detected using human patient sera from an HCV-infected patient. To determine if this patient sample contained Abs that reacted with the HCV core protein, we created cell lysates from two cell lines, the 293 human embryonic kidney line and a 293derived line that constitutively expressed the HCV structural genes. We tested both lysates by Western blot and found that a band that migrated to the area where we would expect the HCV core to migrate was only present in the cell lysate that expressed the HCV structural genes (data not shown).
Northern blot analysis
Total cellular RNA was isolated from transfected 293, 293FL9, and 293B4α cells using the RNAgents RNA Isolation Kit (Promega) as directed by the manufacturer. RNA was separated by size on a 1% agarose/MOPS/formaldehyde gel and transferred to a nitrocellulose filter. HCV RNA was detected with a 32 Plabelled probe, which was prepared by random priming (Amersham Megaprime DNA Labeling System, Piscataway, NJ, USA) using the sequence for the HCV NS3 as template. Control HCV RNA was generated by in vitro T7 polymerase catalyzed transcription of Xho I linearized plasmids using a commercial T7 transcription kit (Epicentre, Madison, Wisc., USA). The transcripts were approximately 9.6 kilobases in size. RNA levels were quantified using the Bio-Rad phosphorimager and Quantity One software package (Hercules, Calif., USA).
Luciferase assay
Luciferase levels were determined in transfected cells (3×10 4 cells per well) using the Bright-Glo Luciferase Assay System as directed by the manufacturer (Promega Corp., Madison, Wisc., USA). Luciferase units were quantified using a TopCount NXT Microplate Scintillation and Luminescence Counter (Packard, Downers Grove, Ill., USA). All luciferase levels were normalized for transfection efficiency using plasmid pSV-β-galactosidase (Promega Corp.).
RT-PCR analysis of HCV RNA
Total cytoplasmic RNA from cells (1×10 6 cells/sample) was isolated using the RNAgents Total RNA Isolation Kit as GCT CAT TCG CGC AGC CAT GTT GGT GCG G N2CAAR CCG CAC CAA CAT GAC TGC GCG AAT GAG C N2CASR
GCT CAT TCG CGC ATG CAT GTT GGT GCG G  5BGAAS  CGA TGC TTG TGT GCG GCG CCG CCC TTG TCG TTA TCT G  5BGAA  CAG ATA ACG ACA AGG GCG GCG CCG CAC ACA AGC ATC G  5BGDDR  CGA TGC TTG TGT GCG GCG ACG ACC TTG TCG TTA TCT G  5BGDDA CAG ATQT ACG ACA AGG TCG TCG CCG CAC ACA AGC ATC G 3PRMS
TAC TTG AAA GGA TGC GCG GGG GGT CCG 3PRMA
CGG ACC CCC CGC GAA TCC TTT CAA GTA 3PRMRS
TAC TTG AAA GGG TGC TCG GGG GGT CCG 3PRMRA
CGG ACC CCC CGA GCA CCC TTT CAA GTA 3HLMS
CAT AAT ATG TGA TGA GTC CCA CTC AAC TGA CTC 3HLMA
GAG TCA GTT GAG TGG GAC TCA TCA CAT ATT ATG 3HLMRS
CAT AAT ATG TGA TGA GTG CCA CTC AAC TGA CTC 3HLMRA
GAG TCA GTT GAG TGG CAC TCA TCA CAT ATT ATG directed by the manufacturer (Promega Corp.). The RT-PCR mixture (50 µl total volume) consisted of 1 µl of purified RNA sample and 0.25 mM each of two oligonucleotides, one of which was complementary to the sense sequence of the luciferase gene (LUCFOR:CCGAGTG-TAGRAAACATTCC) and one that was complementary to the antisense sequence (LUCREV:CTCGCATGCCA-GAGATCC), which resulted in a RT-PCR product of approximately 1000 bp. In addition, the mixture contained reaction buffer, dNTPs and Taq polymerase, which were supplied as components of the Access RT-PCR System (Promega Corp.). RT-PCR was performed as directed by the manufacturer. Two-step, strand-specific PCR was performed by adding only one of the oligonucleotides to the reaction mixture and stopping the RT-PCR after the completion of the RT step. The RT was inactivated at 95°C (15 min), the other oligonucleotide and Taq polymerase were added, and the PCR step was allowed to go to completion.
Actinomycin D treatment of the 293B4α cell line 293B4α cells (1×10 6 cells) were treated with 5 µg/ml actinomycin D treatment. Four hours after actinomycin D treatment began, the cell were treated with 3 H-uridine (25 µCi/ml). Three hours after the addition of the radioactively-labelled uridine, the cells were harvested and total RNA extracted. RNA was separated by size on a 1% agarose/MOPS/formaldehyde gel. The gel was dried and radioactively-labelled RNA was detected by autoradiography.
Results

Expression of the HCV proteins in 293 cells
Plasmid pCX-HCV1b, which contains a cDNA copy of the HCV 1b genome under the control of the chicken β-actin promoter, was transfected by electroporation into 293 cells. Colonies capable of growing in 300 µM G418 were isolated and tested for the production of HCV proteins. From several stably transfected clones, we selected one -designated 293FL9 -which constitutively produced the HCV positive-strand RNA and proteins (HCV NS3, NS5B and core proteins, Figure 1a -c; HCV RNA, Figure 1d ). To create a system in which the production of a reporter protein was dependent upon the reporter's RNA being transcribed by the HCV replicase complex, we placed an antisense copy of the firefly luciferase gene between the 5′ and 3′ UTRs of the HCV-negative strand (Figure 2 ). In addition, the sequence of the hepatitis δ ribozyme was placed 3′ of the 3′ UTR-negative-strand sequence. This construct then was placed under the RW King et al. 356 ©2002 International Medical Press control of the SV40 promoter in pZeoSV to create plasmid, pMJ050. Our hypothesis was that in 293FL9 cells transfected with pMJ050, the SV40 promoter would drive transcription of an mRNA consisting of the 5′UTR (HCV-negative strand) -firefly luciferase in the antisense orientation -3′ UTR (HCV-negative strand) -hepatitis δ ribozyme. The hepatitis δ ribozyme then would cleave itself from the RNA leaving a native HCV-negative strand 3′ terminus. The HCV replication complex would recognize this RNA as a template for the HCV RdRp and transcribe it into the complementary strand. The resultant RNA would consist of the positive-strand 5′ UTR (including the HCV IRES), the luciferase gene in the sense orientation and the positive strand 3′ UTR. Translation of the luciferase gene would be driven by the HCV IRES resulting in the production of detectable and quantifiable luciferase.
To test this hypothesis, pMJ050 was transfected into 293 and 293FL9 cells. Forty-eight hours post-transfection the cells were lysed and luciferase was quantified ( Figure  3a ). 293FL9 cells that were transfected with pMJ050 produced significantly more luciferase than 293 cells transfected with pMJ050, or 293 and 293FL9 cells transfected with pGEM-5z (a control plasmid that does not contain the luciferase gene).
Luciferase production is dependent upon HCV RNA replication enzymes
Once we established that luciferase was produced in 293FL9 cells transfected with pMJ050, we wanted to determine (1) if the HCV RdRp alone was sufficient to produce luciferase, and (2) if not, what HCV proteins were required for luciferase production. 293 cells that were cotransfected with pCX-HCV1b and pMJ050 produced luciferase; however it was approximately 20% less than the level that was produced in 293FL9 cells that had been transfected with pMJ050 (compare Figure 3b and 3a) . When 293 cells were co-transfected with pMJ050 and pRKRdRp, a plasmid that encoded HCV NS5b alone, luciferase not was produced.
To determine if additional HCV proteins were necessary for recognition of the chimeric template, we created plasmids that encoded the full length HCV 1b genome with mutations in the NS2 protease, NS3 protease, NS3 helicase and NS5B RdRp sequences. Previously, these mutations had been shown to inactivate enzyme function (Grakoui et al., 1993 . Plasmids pCX-HCV1b, pRK426 (NS2 -), pRK475 (NS3Pr -), pRK480 (NS3Hel -), and pRK402 (NS5b -) were co-transfected with pMJ050 into 293 cells. Forty-eight hours post-transfection, the cells were lysed and tested for luciferase.
293 cells that were co-transfected with pMJ050 and pRK475 (NS3Pr -), pRK480 (NS3Hel -), or pRK402 (NS5b -) did not produce luciferase (Figure 4 ). Plasmid pRK426 (NS2 -), when transfected with pMJ050 into 293 cells produced approximately 30% of the level of luciferase as cells transfected with pCX-HCV1b plus pMJ050. In addition, 293 cells transfected with pMJ050, pCX-HCV1b, pRK426 (NS2 -), pRK475 (NS3Pr -), pRK480 (NS3Hel -), or pRK402 (NS5b -) individually did not produce detectable levels of luciferase (data not shown).
To show that the mutations in these four plasmids were responsible for the reduction in luciferase levels, the mutations were repaired by site-directed mutagenesis, creating plasmids pRK426 (NS2 -) (wt), pRK475 (NS3Pr -) (wt), pRK480 (NS3Hel -) (wt), and pRK402 (NS5b -) (wt). These plasmids co-transfected into 293 cells with pMJ050 showed levels of luciferase that were equal to that contained in cells co-transfected with pCX-HCV1b and pMJ050.
Creation of a stably-transfected cell line that produces luciferase in an HCV RdRp-dependent fashion
293FL9 cells were transfected with pMJ050 and grown in medium containing the antibiotic zeocin. Thirty days later, 48 zeocin-resistant clones were isolated, expanded, and tested for luciferase production (data not shown). Of these, 11 clones produced luciferase. One clone, which was designated as 293B4α, consistently and reproducibly produced high levels of luciferase ( Figure 5 ). The 293B4α cell line also constitutively produced the HCV core, NS3 protease and NS5b RdRp, as well as the firefly luciferase proteins (data not shown).
Production of luciferase RNA in the 293B4α cell line
To establish if luciferase RNA was produced in both sense and antisense orientations (equivalent to the positive and negative strands of HCV RNA, respectively) in the 293B4α cell line, we isolated total cytoplasmic RNA from the 293B4α, 293FL9 and 293SVLuc cell lines. By using non-quantitative, strand-specific RT-PCR we determined that the 293B4α cell line contained luciferase RNA in both the sense and antisense orientations (Figure 6a, lanes 1 and  2; and Figure 6b, lanes 2 and 3) . 293FL9 cells, whose genome does not contain the luciferase gene, did not contain luciferase RNA (Figure 6b, lane 7) and the 293SVLuc cells, which are stably transfected with the luciferase gene under the control of the SV40 promoter, only contained luciferase RNA in the sense orientation (Figure 6b, lanes 8  and 9) . To establish that this RT-PCR product was actually derived from RNA and not contaminating host or plasmid DNA , the RNA samples were first treated overnight with either DNase or RNase prior to the RT-PCR step. DNase treatment of the RNA samples had no effect on the quantity or quality of the product of either the antisense or sense strand-specific RT-PCR (Figure 6a, lanes 5 and 6) ; however, RNase treatment completely eliminated the ability of both of the strand-specific RT-PCRs to produce a product (Figure 6a, lanes 3 and 4) .
Since DNase treatment is rarely complete, sometimes leaving behind enough DNA to produce a product, we performed the PCR amplification step without including the RT portion. We found that upon elimination of the RT step, no product was seen (Figure 6a, lanes 7 and 8) .
Since the HCV RdRp is resistant to the anti-transcriptional effects of actinomycin D, we treated 293FL9 and 293B4α cells with actinomycin D and determined its effect on luciferase production. Eight hour treatment of 293B4α cells, with 5 µg/ml actinomycin D resulted in a 50% reduction in luciferase expression (data not shown). However, since we could not distinguish between the inhibition of the production of the sense-strand luciferase RNA or the transcription of HCV and antisense-strand luciferase RNAs, we treated 293B4α and 293FL9 cells with actinomycin D for 4 h and then added 3 H-uridine for another 3 h. Total cellular RNA was separated by size and radioactively-labelled RNA was detected by autoradiograghy (data not shown). We found that a radioactively-labelled species of RNA of the correct size (approximately 2300 bases) was detected in the 293B4α sample that was absent in the 293FL9 sample.
Production of luciferase in other human cell lines
It has been reported that the 'HCV-like' RNA in the HCV replicon system replicates only in a certain subclone of HUH-7 cells (Lohmann et al., 1999; Bright et al., 2000) . To determine if our system was also cell specific, we co-transfected three cell lines of human liver origin, HUH-7 (FCCC), HUH-7 (Apath) and Hep G2, and a human cervical carcinoma cell line, HeLa, with pCX- Figure 6 . RT-PCR analysis of the RNA produced in the 293B4α cells Total cytoplasmic RNA was isolated from 293B4α, 293FL9 and 293SVLuc cells. RNA was analyzed in a two-step RT-PCR, which would allow the differentiation of sense and antisense RNA, and a single-step RT-PCR. Lanes labeled 'RNase (+)' and 'DNase (+)' were ones in which the RNA sample was treated with either RNase or DNase prior to the RT-PCR. 'RT(-)' reactions were ones in which the RT step was omitted. S: uncoupled, two-step reactions that would detect the sense sequence of the luciferase gene; A: uncoupled, one-step reactions that would detect the antisense sequence of the luciferase gene, equivalent to the HCV minus-strand; S/A: single-step RT-PCR that does not differentiate between sense and antisense strands.
HCV1b and pMJ050 and determined if luciferase was produced (Figure 7) .
We found that luciferase was produced only in the 293 cell line and in the HUH-7 cell line that was used to create the replicon system, HUH-7 (Apath). Luciferase was not detected in the other HUH-7 subclone, HUH-7 (FCCC) or in HepG2 and HeLa cells.
Discussion
The lack of a suitable cell culture system that allows the replication of HCV has hindered the understanding of the molecular biology of the HCV replication cycle and the development of new therapies for HCV infection. Although several new cell-based systems recently have been described as models for HCV replication, they only model a portion of the virus' replication cycle (Goobar-Larsson, 2001 , Lohmann et al., 1999 , Moradpour et al., 1998 , Myung et al., 2001 , Pietschmann et al., 2001 . In addition, detecting and quantifying the level of virus replication is difficult in these systems relying on either Western or Northern blot analysis, or quantitative RT-PCR. In this study, we described a cell culture system that models the production and processing of the HCV polyprotein, as well as replication and IRES-dependent translation of a chimeric 'HCV-like' RNA.
The advantage of this system is that these three processes can be quickly and easily monitored and quantified. This is accomplished by quantifying the level of luciferase, whose production is dependent upon the replication of the negative-strand 'HCV-like' RNA into the positive-strand (or coding) orientation so that it can be translated in an IRES-dependent fashion. In the 293B4α cell line, an integrated cDNA copy of the HCV 1b genome provides the necessary viral components for the replication of this RNA.
This reporter construct consisted of the 5′ UTR of the HCV-negative strand, the firefly luciferase gene in the antisense orientation, the 3′ UTR of the HCV negative strand, and the hepatitis δ ribozyme. The strategy was that the DNA-dependent RNA polymerase that is provided by the cell would transcribe this sequence into RNA. After transcription, the hepatitis δ ribozyme would be removed through a cis cleavage event, resulting in an 'HCV-like' RNA whose 3′ terminal sequence is exactly the same as that found in the wild-type virus.
The critical question was if the HCV RdRp in the 293FL9 cell line would recognize the reporter RNA as a template for RNA replication. Others have shown previously that in an in vitro enzyme system, the HCV RdRp can utilize a variety of templates including ones that are and are not derived from the HCV genome (Kolykhalov, 1996; Tanaka et al., 1996; Luo et al., 2000) . Moreover, the HCV RdRp is able to utilize poly(C) and poly(A) templates if the appropriate primers are supplied (DeFranscesco et al., 1996) .
Recently, it was shown that in an intracellular environment the HCV RdRp could recognize a series of templates (Goobar-Larsson et al., 2001) . The templates were not restricted to ones that had HCV-specific sequences but activity was higher with those that contained the positiveand negative-strand 3′ UTR sequences. Interestingly, the HCV RdRp was active even when still part of the HCV polyprotein; however, activity was diminished. Moreover, cleavage of the RdRp from the polyprotein had no effect on template usage or specificity. Finally, RdRp activity was greatest when the RdRp was in the presence of the other HCV nonstructural proteins.
To determine if the HCV RdRp produced in the 293FL9 cell line could use an 'HCV-like' template, we transfected pMJ050 into the cells and assayed for RW King et al. 360 ©2002 luciferase. We found that luciferase was produced in transfected 293FL9 cells but not in transfected 293 cells. Cotransfection of 293 cells with a plasmid that encodes the entire HCV-1 1b genome and pMJ050 resulted in luciferase production; whereas co-transfection of 293 cells with a plasmid that encodes only the HCV NS5b and pMJ050 did not. Moreover, co-transfection of 293FL9 cells with pMJ050 and plasmids that encoded cDNA copies of the HCV genome that contained mutations which inactivated the HCV NS2 protease, NS3 protease, NS3 helicase and NS5B RDRP, respectively, resulted in significantly reduced or background levels of lucifease. These data showed that in this system the HCV RdRp is essential but not sufficient for utilizing the chimeric 'HCVlike' RNA as a template for negative-to positive-strand replication. This is in disagreement with the observations of Goobar-Larsson et al. (2001) . It had been shown previously that the mutations that we had engineered into the NS2 sequence had completely inhibited the activity of the protease (Grakoui 1993) ; therefore, it was unexpected that the NS2 -HCV 1b genome could still drive production of luciferase. We speculate that in the cellular environment, NS3 in the uncleaved NS2/NS3 state may still be functional but at a reduced level.
The HCV replicon systems that have been described previously have identified several mutations that have been selected for by continuous passage of the cells (Blight et al., 2000; Krieger et al., 2001; Lohmann et al., 2001) . These mutations increased HCV RNA replication and enhanced the efficiency of colony formation. A survey of the HCV 1b sequence that we used to create the 293FL9 cell line showed that this genome lacked any of the mutations that conferred cell culture adaptation in the replicon systems (data not shown). We hypothesize that these adaptive mutations may not be necessary in our system because we are not looking at (1) replication of the HCV genome itself but instead at an 'HCV-like' RNA template that is approximately 1/5 the size of the HCV genome, and (2) we only are looking at the replication of a continuously-produced, negative-strand-like RNA to a positive-strand-like RNA. Our system does not require the continuous synthesis of both negative-and positive-strand RNA from an input strand of RNA as in the replicon system.
Using the zeocin-resistance gene that was encoded by pMJ050, we isolated several 293FL9 clones that contained integrated copies of the antisense luciferase reporter construct. These clones were assayed for luciferase activity and the 293B4α cell line was selected based on its high levels of luciferase production. Western blot analysis showed that this cell line synthesized the HCV core, NS3 protease and NS5B RDRP and the firefly luciferase proteins. In addition, RT-PCR demonstrated that both the noncoding and coding RNA transcripts of the luciferase gene (representative of the negative and positive species of HCV RNA) were produced.
It has been difficult to validate that luciferase expression in the 293B4α cell line is dependent upon the HCV proteins and is not the result of the reporter cassette inserting into the cellular genome in such a way that transcription of the luciferase (and antisense luciferase) RNA is being driven by cellular promoters. Since this is a stably-transfected system, it is not possible to do the type of genetic experiments that we did with the transient-transfection system. One of the classic methods of showing that RNA synthesis is occurring through RdRp activity is to show that transcription occurs in the presence of actinomycin D since viral RdRps are resistant to the anti-transcriptional activity of actinomycin D. However, since transcription of the HCV and the antisense luciferase RNAs are driven by eukaryotic promoters, actinomycin D would inhibit transcription of these RNAs, leading to an overall reduction in luciferase expression. To try to circumvent this problem, 293FL9 and 293B4α cells were treated with actinomycin D and then labelled with 3 H-uridine. A radioactively-labelled RNA species of the expected size was detected in 293B4α but not 293FL9 cells.
The greatest utility of this system lies in the fact that the HCV RdRp can recognize and reproduce an 'HCV-like' template in the environment of the cell. If the template is a reporter gene, as in this example, then HCV replication can be detected and quantified easily, accurately and reproducibly. This ability to easily quantify HCV replication will be essential if we are to gain a better understanding of the molecular biology of the HCV replication cycle. Moreover, this system would be quite amenable for use in the identification of chemical compounds that contain antiviral activity against HCV. In fact, we have formatted the 293B4α cell line into a medium-throughput cell-based assay that has allowed us to identify the anti-HCV activity of nucleoside analogues, interferon-α and -β (King et al., 2002) , as well as low molecular weight, non-nucleoside inhibitors of the HCV RdRp, NS2 protease and NS3 protease (data not shown).
One of the drawbacks to this system is that it can not be used to study the production of HCV-negative-strand RNA from positive-strand since the 'negative-strand' of the 'HCV-like' reporter RNA is constitutively transcribed from DNA under the control of the SV40 promoter. This promoter is such a strong promoter that the large amount of 'negative-strand-like' RNA produced from this transcriptional process would overshadow the small quantity of 'negative-strand-like' RNA produced from the use of the positive-strand-like RNA by the HCV RdRp. Moreover, it is not possible to study the production of negative-strand RNA from the positive-strand template using the produc-tion of HCV negative-strand RNA from HCV positivestrand in this system because the HCV RNA encoded by pCX-HCV1b is poly-adenylated and does not serve as a template for the HCV RdRp in our system.
Finally, as has been reported for the replicon system, there also is cell specificity in our system. The 293 and HUH-7 (Apath) cell lines, which supported the production of luciferase in an HCV protein-dependent manner, must contain certain factors that are necessary for the replication of the chimeric 'HCV-like' RNA, which are absent in the HUH-7 (FCCC), Hep G2, and HeLa cell lines. These factors have yet to be identified.
